Results 101 to 110 of about 1,591,431 (356)

Post vaccinal temporary sensorineural hearing loss [PDF]

, 2018
In our systematic research we identified four studies concerning the onset of neurological adverse events following vaccination and two excluding this association.
De Cesare, Donato Pompeo, De Marco, Federica, Di Folco, Francesco, Di Luca, Natale Mario, Massoni, Francesco, Ricci, Serafino, Sacco, Carmina, Tomei, Francesco, Tomei, Gianfranco   +8 more
core   +1 more source

Inactivating SARS‐CoV‐2 Virus with MOF‐Composites as Smart Face Masks

Advanced Functional Materials, EarlyView.
In situ preparation and functionalization of MOF@Cotton fabrics as smart face masks for the immobilization of proteins and inactivation viruses, such as SARS‐CoV‐2. Abstract The significant impact of the SARS‐CoV‐2 (COVID‐19) pandemic outbreak on people's lives has highlighted the urgent need for effective personal protective equipment.
Romy Ettlinger, Aamod V. Desai, Hau Lam Jody Cheong, Louise L. Major, Terry K. Smith, Aaron B. Naden, Jane Hilton, Catherine S. Adamson, A. Robert Armstrong, Russell E. Morris   +9 more
wiley   +1 more source

Biomimetic Nanovaccine Integrating Dendritic Cell Exosomes with Tumor Cell Membranes for Sustained Prophylaxis Against Glioblastoma

Advanced Functional Materials, EarlyView.
We have developed DEX/GM, an all‐natural, personalizable hybrid vaccine designed by coating dendritic cell‐derived exosomes (DEX) onto tumor cell membranes (GM) for sustained prophylaxis against glioblastoma (GBM). ABSTRACT Glioblastoma (GBM), one of the most aggressive and lethal brain tumors, remains incurable with a poor clinical prognosis.
Shanshan Li, Dongya Zhang, Shiyu Wang, Changhe Pang, Meng Zheng, Bingyang Shi, Yan Zou   +6 more
wiley   +1 more source

Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial

Human Vaccines & Immunotherapeutics, 2017
This phase III, non-randomized, open-label, multi-center study (NCT01827839) evaluated the immunogenicity and safety of an adjuvanted recombinant subunit herpes zoster (HZ) vaccine (HZ/su) in adults aged ≥ 50 y with prior physician-documented history of ...
Olivier Godeaux, Martina Kovac, Daniel Shu, Katrijn Grupping, Laura Campora, Martine Douha, Thomas C. Heineman, Himal Lal   +7 more
doaj   +1 more source

Racing against COVID-19: a vaccines strategy for Europe. Bruegel Policy Contribution Issue n˚7 | April 2020 [PDF]

, 2020
The fast development of vaccines is an essential part of the long-term solution to COVID-19, but vaccine development has high costs and carries the risk of high failure rates.
Veugelers, Reinhilde, Zachmann, Georg.
core   +1 more source

Poly(lactic‐co‐glycolic acid) Nanoparticles for IL‐12 Self‐Amplifying RNA Delivery in Glioblastoma Models

Advanced Functional Materials, EarlyView.
xxxx. ABSTRACT Glioblastoma (GBM) remains one of the most lethal brain cancers, with median survival rarely exceeding 15 months after diagnosis. Interleukin‐12 (IL‐12) is a potent immunostimulatory cytokine capable of reshaping the tumor microenvironment (TME), yet its clinical translation is hindered by systemic toxicity and short half‐life. RNA‐based
Fatima Hameedat, Johan Sebastian Lopez‐Parra, Willem M. H. Hoogaars, Emma Dijkstra, Cynthia Huang, Irafasha C. Casmil, Anna K. Blakney, Peter Olinga, Barbara Rothen‐Rutishauser, Hélder A. Santos, Alke Petri‐Fink, Flávia Sousa   +11 more
wiley   +1 more source

Mechanism of action of mRNA-based vaccines

Expert Review of Vaccines, 2017
Introduction: The present review summarizes the growing body of work defining the mechanisms of action of this exciting new vaccine technology that should allow rational approaches in the design of next generation mRNA vaccines.
Carlo Iavarone, Derek T. O’hagan, Dong Yu, Nicolas F. Delahaye, Jeffrey B. Ulmer   +4 more
doaj   +1 more source

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

npj Vaccines, 2022
Without clinical efficacy data, vaccine protective effect may be extrapolated from animals to humans using an immunologic marker that correlates with protection in animals. This immunobridging approach was used for the two-dose Ebola vaccine regimen Ad26.
Viki Bockstal, Maarten Leyssen, Dirk Heerwegh, Bart Spiessens, Cynthia Robinson, Jeroen N. Stoop, Ramon Roozendaal, Thierry Van Effelterre, Auguste Gaddah, Griet A. Van Roey, Laura Solforosi, Roland Zahn, Benoit Callendret, Jenny Hendriks, Kerstin Luhn, Macaya Douoguih, Hanneke Schuitemaker, Johan Van Hoof   +17 more
doaj   +1 more source

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

Advanced Functional Materials, EarlyView.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source

A gorilla adenovirus-based vaccine against Zika virus induces durable immunity and confers protection in pregnancy [PDF]

, 2019
The teratogenic potential of Zika virus (ZIKV) has made the development of an effective vaccine a global health priority. Here, we generate two gorilla adenovirus-based ZIKV vaccines that encode for pre-membrane (prM) and envelope (E) proteins (GAd-Zvp ...
Brough, Douglas E, Curiel, David T, Diamond, Michael S, Dmitriev, Igor P, Fremont, Daved H, Hassan, Ahmed O, Kashentseva, Elena A, Zhao, Haiyan   +7 more
core   +1 more source